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Infections Associated with Bartonella Species in Persons Infected with Human 
Immunodeficiency Virus 
Russell L. Regnery, James E. Childs, From the Viral and Rickettsial Zoonoses Branch, Division of Viral and 
and Jane E. Koehler Rickettsial Diseases, Centers for Disease Control and Prevention, 
Atlanta, Georgia; and the Division of Infectious Diseases, University of 
California, San Francisco, California 
Two members of the genus Bartonella, Bartonella quintana (formerly Rochalimaea quintana) and 
Bartonella henselae (formerly Rochalimaea henselae), have recently been recognized as agents of 
severe or fatal disease in patients infected with human immunodeficiency virus (HIV). The develop- 
ment of infection with B. henselae in HIV-infected individuals has been associated with traumatic 
contact with cats (scratches or bites), and domestic cats have been identified as a major reservoir 
for this organism. Specific information regarding the transmission of B. henselae to humans is not 
yet available, but common-sense precautions that minimize exposure to cat-associated organisms 
are appropriate. Preliminary accounts suggest that B. quintana infections are more common than 
B. henselae infections among HIV-infected individuals in San Francisco. The source of infection 
with B. quintana and the mechanism of its transmission remain unknown. 
The four species of the genus Rochalimaea (Rochalimaea 
quintana, Rochalimaea henselae, Rochalimaea elizabethae, 
and Rochalimaea vinsonii) were recently shown to be closely 
related to the sole member of the genus Bartonella (Bartonella 
bacilliformis) [1]. Because Bartonella was described before 
Rochalimaea, the former designation takes precedence over the 
latter. Thus the name Bartonella will be used in this document 
to describe all five members of the expanded genus. However, 
in many publications the name Rochalimaea may still be used. 
Species names remain unchanged; e.g., R. henselae is now 
known as Bartonella henselae. 
Background 
The diseases known to be associated with Bartonella species 
are listed in table 1. Historically, the best-known member of 
the genus is Bartonella quintana, the bacterium that caused 
trench fever in World War I [2]. In 1990, DNA sequences 
closely related to B. quintana were identified in the lesions 
of patients with bacillary angiomatosis (BA) [3], a vascular 
proliferative disorder that occurs in HIV-infected persons [4]. 
Independently, a fastidious gram-negative rod was isolated 
from HIV-infected patients with a relapsing febrile illness [5], 
and similar bacilli were noted in tissue from patients with an 
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unusual hepatic disease known as peliosis hepatis [6]. A novel 
species, B. henselae, was later isolated and fully characterized 
[7, 8]. Gene sequences from B. henselae were identical to those 
previously identified in biopsied tissues from patients with BA 
and peliosis hepatis [3, 7]. The subsequent isolation of bacteria 
directly from cutaneous lesions of BA revealed that either B. 
henselae or B. quintana can cause this disease [9]. Over the 
past decade, since BA was first described by Stoler et al. in 
New York City [10], the spectrum of bartonella infection in 
patients with concomitant HIV infection has been expanding; 
now included are endocarditis [11, 12] and angiomatous lesions 
involving many organs, including the skin, liver, lung, spleen, 
bone, and brain. (For a summary of the involvement of various 
organs, see [13].) Although cutaneous BA can be an indolent 
disease with remissions and exacerbations over many months 
[4], its systemic symptoms can be debilitating. When bartonella 
infection remains undiagnosed in patients with HIV infection, 
it can be fatal [14]. 
Recently, B. henselae was found to be the cause of cat- 
scratch disease [15-17] in addition to some cases of BA. The 
reason for the different host responses to infection with 
B. henselae (granulomatous in the immunocompetent host and 
vascular proliferative in the immunocompromised host) is un- 
known. Immunocompetent people with B. henselae infection 
can develop a prolonged febrile and relapsing illness [18] like 
that seen in HIV-infected patients [5, 7]. 
Infection with the remaining three Bartonella species has not 
been reported in HIV-infected patients. Bartonella elizabethae 
caused severe endocarditis in one immunocompetent patient 
[19]. No human infections with Bartonella vinsonii have been 
identified. B. bacilliformis, the etiologic agent of bartonellosis, 
causes biphasic illness: the acute febrile phase is known as 
Oroya fever, and the chronic phase with cutaneous vascular 
lesions is known as verruga peruana [20]. These cutaneous 
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Table 1. Diseases with well-documented associations with Barto- 
nella species. 
Immune status, disease Causative species of Bartonella 
Competent 
Cat-scratch disease B. henselae 
Trench fever B. quintana 
Bartonellosis B. bacilliformis 
Endocarditis B. henselae, B. quintana, B. elizabethae 
Compromised 
Bacillary angiomatosis B. henselae, B. quintana 
Relapsing bacteremia with fever B. henselae, B. quintana 
Endocarditis B. henselae, B. quintana 
eruptions are sometimes indistinguishable from those of BA; 
however, infection with B. bacilliformis has been reported only 
in the Andes Mountains of South America [20]. 
Numerous reports in the literature describe good clinical 
responses of immunocompromised patients with BA or peliosis 
hepatis to treatment with erythromycin or doxycycline. In the 
experience of one of the authors (J.E.K.), erythromycin, doxy- 
cycline, tetracycline, and minocycline have been successful in 
the treatment of these conditions (table 2) [13]. Rifampin and 
gentamicin appear to have some clinical efficacy; although 
there is insufficient evidence to recommend the use of either 
agent alone, these drugs may be of value when combined with 
a first-line agent for the treatment of immunocompromised 
patients with severe Bartonella-associated isease (e.g., osteo- 
myelitis, peliosis hepatis, or endocarditis). There are conflicting 
reports regarding the response of BA lesions in immunocom- 
promised patients to treatment with quinolones [13]. 
The optimal duration of treatment for immunocompromised 
individuals is unknown, but patients with cutaneous BA should 
receive an appropriate antibiotic for at least 2 or 3 months; 
patients with more severe disease (osteomyelitis, peliosis hep- 
atis) should receive a minimum of 3 or 4 months of antibiotic 
therapy. Most patients treated with tetracycline or erythromycin 
for 4 months do not have a relapse. However, like salmonellosis 
and various other bacterial infections, bartonella infection can 
relapse in some cases even after prolonged therapy with eryth- 
romycin [9]. Immunocompromised patients with bartonella in- 
fection should be followed closely if antibiotic treatment is 
stopped after 4 months; if a relapse occurs, these individuals 
should be treated indefinitely with suppressive antibiotics. 
Although the clinical response to antibiotics is dramatic 
among immunocompromised patients with bartonella infection, 
the response of people with intact immune systems and cat- 
scratch disease or relapsing bacteremia remains equivocal [18, 
21]. The curious influence of the host's immune status on 
apparent antibiotic efficacy may be related to different manifes- 
tations of the syndromes. Cat-scratch disease is clinically de- 
fined by swollen lymph nodes and granulomatous lesions- 
signs that cannot develop in severely immunocompromised 
hosts and that cannot be expected to regress as long as antigen is 
present. It is possible that persons with intact immune systems, 
unlike severely immunocompromised patients, sequester viable 
or antigenically active Bartonella within either cells or im- 
mune-mediated tissue complexes (e.g., granulomas). 
Incidence 
Preliminary estimates of the prevalence of antibody to Barto- 
nella among apparently healthy humans range from 4% to 
6% [15, 22]. Cat-scratch disease is clinically diagnosed in an 
estimated 22,000 persons each year in the United States [23]. 
The incidence of Bartonella-associated isease among HIV- 
infected persons is unknown. These infections may go unrecog- 
nized in the majority of cases, and the interval between infec- 
tion and the diagnosis of BA can cover months or even a year 
[9]. In addition, disease in immunocompromised persons may 
represent reactivation of infection rather than primary infection: 
low-titer antibodies to Bartonella have been documented in 
banked sera obtained from HIV-infected people before the 
diagnosis of BA, with increased titers at the time of diag- 
nosis [24]. 
Bartonella infections in HIV-infected people often are not 
recognized for a number of reasons. First, cutaneous BA lesions 
can be clinically indistinguishable from Kaposi's sarcoma [25]; 
in these cases, BA can be distinguished only by biopsy with 
histopathologic examination. A characteristic vascular prolifer- 
ation with a mixed inflammatory infiltrate is evident upon he- 
matoxylin and eosin staining of biopsied BA tissue, and bacil- 
lary organisms can be demonstrated by Warthin-Starry staining 
[4]. Second, hepatic disease caused by Bartonella species- 
even the relatively dramatic form, peliosis hepatis-can be 
indistinguishable from other infectious or malignant conditions 
that cause hypodense lesions demonstrable by abdominal CT 
(e.g., lymphoma, Kaposi's sarcoma, extrapulmonary pneumo- 
cystosis, and bacterial and fungal abscesses). Third, clinicians 
evaluating HIV-infected patients may fail to consider Barto- 
Table 2. Clinical response of HIV-infected individuals with bacil- 
lary angiomatosis or peliosis hepatis to antibiotic treatment (San Fran- 
cisco General Hospital/University of California t San Francisco, 
1987-1995). 
Definite Possible Inconclusive None 
Erythromycin Gentamicin Ciprofloxacin Penicillin 
Doxycycline Rifampin Ceftriaxone Penicillin 
derivatives 
Tetracycline Trimethoprim/ First generation 
sulfamethoxazole cephalosporins 
Minocycline 
NOTE. Table is adapted with permission from [13]. 
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Table 3. Manifestations of bartonella infections in HIV-infected 
patients. 
Organ Manifestation 
Skin (bacillary Diverse presentations, including lesions 
angiomatosis) resembling Kaposi's sarcoma, angiomatous 
nodules, friable vascular lesions, red papules, 
pedunculated lesions, and deep subcutaneous 
masses 
Bone Extremely painful osteolysis, lytic lesions on 
radiography (positive technetium scan) 
Lymph node Enlargement 
Heart Valvular vegetation, fever, weight loss 
Blood Fever, thrombosis 
Liver/spleen bacillary Hypodense lesions, hepatosplenomegaly on CT, 
peliosis elevated values in liver function tests (e.g., 
alkaline phosphatase), pancytopenia, 
thrombocytopenia 
Other Involvement of brain, gastrointestinal tract, 
lungs, etc. 
NOTE. Table is adapted from [26]. 
nella in the differential diagnosis of a febrile illness in the 
absence of cutaneous lesions or peliosis hepatis (table 3) [26]. 
Finally, culture of Bartonella species is difficult, requiring 
special media and techniques. This situation compounds the 
problems encountered in the diagnosis of isolated bartonella 
bacteremia, even when this diagnosis is considered. A genus- 
specific IgG indirect fluorescent antibody (IFA) test recently 
developed at the Centers for Disease Control and Prevention 
(CDC) is both sensitive and specific for the confirmation of a 
diagnosis of cat-scratch disease [15, 22]. Patients with cat- 
scratch disease typically have elevated titers of Bartonella- 
specific IgG antibody at the time of their presentation to the 
health care practitioner; titers appear to diminish within a year 
of the original diagnosis [22]. The diagnosis of cat-scratch 
disease by IFA test has correlated well (98%; 55 of 56 cases) 
with clinical diagnosis and skin testing [27], and the specificity 
of the IFA test is -95% [15, 22]. An IgM ELISA has also 
shown relatively good sensitivity (95%; 53 of 56 cases) in 
studies of patients with cat-scratch disease diagnosed by skin 
testing; however, the specificity of the ELISA was only 77% 
(43 of 56 cases) [27]. Preliminary results suggest that the IFA 
test shows promise in the laboratory confirmation of bartonella 
infections in HIV-infected patients [24]. Improved diagnostic 
tests will result in more accurate assessment of the true inci- 
dence of bartonella infection in this population and may 
facilitate appropriate treatment. Reagents for IFA testing for 
Bartonella are currently available to regional and state health 
laboratories from the CDC. Additional diagnostic techniques 
for the serological testing of patients (including commercial 
tests) are being developed. However, before their widespread 
use as diagnostic tools, additional blinded, side-by-side evalua- 
tions of specificity and sensitivity for the various Bartonella- 
associated syndromes are necessary. 
Source of Infection and Risk Factors 
Numerous anecdotal reports have described exposure to and 
contact with cats before the development of BA in immuno- 
compromised patients [13]. A case-control analysis found that 
recent contact with cats was the only environmental risk factor 
associated with BA [28]. Patients with BA-but not control 
patients-were statistically more likely to have been licked, 
scratched, or bitten by a cat before developing this illness. The 
amount of time spent with a cat was associated with the degree 
of risk. As had previously been documented in studies of cat- 
scratch disease in HIV-uninfected populations [22, 29], owner- 
ship of kittens or young cats (i.e., those <1 year old) posed a 
particularly high risk to HIV-infected persons for acquiring 
B. henselae-associated disease [28]. 
It has recently been shown that the domestic cat provides a 
major reservoir from which HIV-infected patients apparently 
acquire B. henselae infection. Seven pet cats belonging to four 
patients with confirmed BA due to B. henselae had this organ- 
ism isolated from the bloodstream, as did 25 (41%) of 61 
randomly sampled cats in San Francisco [30]. Seroepidemio- 
logical studies indicate that B. henselae infection of domestic 
cats is also common in other regions of the United States, with 
a prevalence of Bartonella-specific antibodies ranging from 
14% to 50% [22, 31]. An estimated one-third of all households 
in the United States include a cat [32], and cats may be persis- 
tently bacteremic for prolonged periods without obvious signs 
of illness [30, 33]. Thus, pet cats pose a real but probably small 
risk of B. henselae infection to HIV-infected owners [34]. 
Exposure to kittens with fleas has been reported to be a risk 
factor for cat-scratch disease. Thus, it has been suggested that 
arthropod vectors transmit B. henselae among felines and/or 
between felines and humans, although a cat scratch or bite has 
been more strongly associated with acquisition of the disease 
[22]. Viable B. henselae bacilli have been isolated from fleas 
from cats [30], but the fleas' ability to transmit B. henselae 
has not been established. Ticks also have been suggested as 
possible vectors of B. henselae [18, 22]. 
Early in the investigation of Bartonella-associated iseases, 
the human body louse (Pediculus humanus) was identified as 
a vector of human-to-human transmission of B. quintana [2]. 
However, virtually nothing is known about possible arthropod 
vectors or possible alternative vertebrate reservoirs of 
B. quintana infections today. B. bacilliformis can be transmitted 
by the sandfly (genus Phlebotomus) within its naturally oc- 
curring geographic range [20]. Neither nonhuman reservoirs 
nor possible arthropod vectors of B. elizabethae are known. 
Because infections with B. bacilliformis and B. quintana can 
be arthropod-bome, it is plausible that other members of the 
genus (e.g., B. henselae) also have arthropod vectors. 
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The risk of developing relatively severe disease due to Barto- 
nella species appears to increase as the CD4+ cell count de- 
creases. In a recent review, the mean CD4+ cell count of 15 
HIV-infected patients with Bartonella-associated isease was 
57/mm3 [13]. In a case-control study of 42 patients with barto- 
nella infection, patients with BA were statistically more likely 
than controls to have a CD4+ cell count of <200/mm3 [35]. 
Prevention 
Physicians should recognize the potential psychological 
value of companion animals for seriously ill persons. However, 
immunocompromised persons who have no prior emotional 
attachment o a cat and who are concerned about the risk of 
B. henselae infection should consider alternative species for 
companionship. Of course, the potential for zoonotic disease 
associated with nonfeline companion-animal species also must 
be considered [34]. 
Because data are not yet available on the degree of risk to 
humans for B. henselae infection related to contact with cats 
or on the mode of B. henselae transmission from one cat to 
another or from cats to humans, specific recommendations for 
prevention are currently limited to common-sense precautions 
[34, 36]. Adult cats pose a lesser risk than do cats <1 year 
old. Severely immunocompromised persons should avoid 
rough play with cats that might result in scratches or bites and 
should not allow a cat to lick open cuts or wounds. Contamina- 
tion of broken skin with cat secretions should be avoided, 
and cat-associated wounds should be washed immediately with 
soap and water. Control of fleas is appropriate. 
Recommendations regarding the prevention of B. quintana 
infection are presently limited to the avoidance of exposure to 
the human body louse. 
Research Priorities 
Bartonella-associated isease among HIV-infected persons 
has been described only recently, but it is already evident that 
treatment and preventive efforts can be beneficial. The inci- 
dence of Bartonella-associated isease must be established, 
and the spectrum of disease (including syndromes currently 
undiagnosed) must be more completely elucidated. Economi- 
cal, rapid, sensitive, and specific methods for laboratory diag- 
nosis need to be further developed and disseminated to local 
health care centers. The timing, type, and duration of antibiotic 
prophylaxis for initial or reactivated bartonella infection in 
HIV-infected persons (especially those who are seropositive 
for Bartonella) should be considered. The development of mi- 
crobial resistance is a theoretical possibility during prolonged 
antimicrobial therapy. 
More complete analyses of risk factors for infections due to 
B. henselae and B. quintana must be undertaken. The route by 
which cats become infected with B. henselae and the way in 
which this organism persists in and is subsequently transmitted 
by these animals should be established. The potential for the 
elimination of feline infections due to B. henselae by antibiotic 
treatment and for the prevention of reinfection must be studied. 
A feline vaccine designed to prevent B. henselae infection 
should be developed, with the interruption of transmission to 
HIV-infected pet owners as the ultimate goal. The possible 
role of arthropod vectors in the transmission of B. henselae 
and B. quintana needs to be clarified. 
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